Skip to main content
. 2017 Sep 10;2017:9703574. doi: 10.1155/2017/9703574

Figure 4.

Figure 4

The mitochondrial respiration results and SIRT3 expression/activity in patients with movement disorders (n = 57) with respect to treatment (1) and no treatment (0) using (a) levodopa (L-DOPA; A0, n = 6; A1, n = 51); (b) dopamine (DA) receptor agonists ropinirole and pramipexole (B0, n = 20; B1, n = 37); (c) selegiline (C0, n = 52; C1, n = 5); (d) rasagiline (D0, n = 47; D1, n = 10); and (e) amantadine (E0, n = 28; E1, n = 29). The results are expressed as median (interquartile range).